|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **First author** | **Year of publication** | **Country** | **Age**  **(M/F)** | **Group Infiltration** | | **Group ISB** | | **Outcomes** | **Follow-up** |
| **Nb of patients** | **Drugs and dose** | **Nb of patients** | **Drugs** |
| Abildgaard | 2017 | USA | 68.9  (35/48) | 36 | 20 mL (266 mg) LB | 47 | Ropivacaine 0.5%, 8mL/h | -VAS score  -Opioid consumption | 90 days |
| Ali | 2021 | USA | 66.5±9.1  (61/47) | 54 | 20 mL of liposomal bupivacaine | 54 | 10 to 20 mL of ropivacaine 0.5% | -VAS score  -Opioid consumption | 96 hours |
| Bingol | 2021 | Turkey | 52.1±12.7  (32/28) | 30 | 60 mL of local anesthetic | 30 | 20 mL of Bupivacaine 0.5% | -VAS score | 90 days |
| Bjørnholdt | 2015 | Denmark | 65.5 ± 8  (24/37) | 30 | 150 ml ropivacaine 0.2 % with epinephrine | 31 | Ropivacaine 0.75 %, 7 ml bolus then 5 ml/h | -VAS score  -Opioid consumption | 90 days |
| Klag | 2020 | USA | 69.4 ± 8.1  (31/30) | 30 | 200 mg of 0.5% ropivacaine, 1 mg epinephrine, and 30 mg ketorolac | 31 | 40 mL of 0.5% ropivacaine | -VAS score  -Opioid consumption | 3 days |
| Michael | 2022 | Columbia | 69 (52/22) | 37 | - | 37 | - | -VAS score  -Opioid consumption | 24 hours |
| Namdari | 2017 | USA | 69.6 ± 9  (71/85) | 78 | 266 mg of 1.3% bupivacaine diluted in 20 mL of saline solution | 78 | 30 mL of 0.5% ropivacaine | -VAS score  -Opioid consumption | 24 hours |
| Okoroha | 2016 | USA | 68.8  (28/29) | 26 | 20 mL of LB (266 mg) mixed in 20 mL of sterile saline | 31 | 40 mL of 0.5% ropivacaine | -VAS score  -Opioid consumption | 4 days |
| Panchamia | 2019 | USA | 68.6 ± 11  (45/39) | 42 | 120 mL of ropivacaine 0.5%, epinephrine and ketorolac | 42 | 15-20 ml Bupivacaine 0.5% with epinephrine | -VAS score  -Opioid consumption | 16 weeks |
| Sabesan | 2017 | USA | 64  (44/26) | 34 | 20-mL (266-mg) dose of LB was diluted to a total volume of 80 mL with 0.9% normal saline | 36 | 20-mL single bolus with 0.5% bupivacaine then 0.125% bupivacaine at a rate of 6 mL/h | -VAS score  -Opioid consumption | 30 days |
| Shumaier | 2023 | USA | 67.5  (42/34) | 38 | 20 mL of liposomal bupivacaine | 38 | 20 to 30 mL of Ropivacaine 0.5% | -VAS score  -Opioid consumption | 14 days |
| Sicard | 2018 | France | 72 ± 9.6  (35/64) | 50 | 110 mL of 0.2% ropivacaine, 30 mg of ketoprofen and 0.5 mg of epinephrine | 49 | 20 ml of ropivacaine 0.2% then infusion 5 ml/h | -VAS score  -Opioid consumption | 30 days |

M/F (male/female), ISB (interscalene brachial plexus block), LB (liposomal bupivacaine), VAS (visual analog scale), mL (milliliters), mg (milligrams), h (hours), and USA (United States of America).